Market Cap
$3.0B
ZLAB
Zai Lab Ltd
$24.33 ▼ -4.59%
Prev close $25.50Market cap$3.0B
ConsensusStrong Buy
12-mo target$33.14 (+36.2%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)10 New Institutional Positions10 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on ZLAB right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (80%)
Inst. Holders
50 funds
Inst. Value
$538.2M
Inst. Activity
10 buys / 10 sells
Insider Activity
$33.1K buy / $5.3M sell
Insider Net $
-$5.3M
SEC Reports
20
Price chart 30d -9.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Nov 30, 2026 fda_pdufa
Aug 22, 2026 SEC PDUFA: ZLAB — povetacicept in immunoglobulin A nephropathy (IgAN) — 2026-11-30
FDA target action date 2026-11-30 for ZLAB (Zai Lab Ltd). Drug: povetacicept. Indication: immunoglob
Two Zai Lab insiders — Director William Lis and CFO Yajing Chen — sold a combined $220K in open-market sales over an 8-d
CLUSTER — Impact 2/10
A small insider selling cluster at Zai Lab involved a director selling $213K in open-market shares and the CFO surrender
CLUSTER — Impact 2/10
Aug 19, 2026 Insider
Aug 14, 2026 SEC Chen Yajing sold 260 shares
Chief Financial Officer @ $27.00 ($7.0K)
Two Zai Lab insiders, including CFO Chen Yajing and Director Lis William, sold a combined $228K in open-market sales ove
CLUSTER — Impact 2/10
Aug 14, 2026 Insider
Chen Yajing acquired via exercise 1,250 shares
Chief Financial Officer
Aug 14, 2026 Insider
Chen Yajing surrendered for taxes 427 shares
Chief Financial Officer @ $25.90 ($11.1K)
Jun 30, 2026 Inst.
FMR LLC — DOUBLED
2,815,214 shares ($53.5M)
Analyst ratings buy % +1.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
80% rate it Buy or better · 15 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 7, 2026 | Citigroup | MAINTAIN | Buy | 55% |
| May 8, 2026 | Citigroup | MAINTAIN | Buy | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 10 | 3 | 0 | 0 | 80% | |
| Aug 1, 2026 | 2 | 9 | 3 | 0 | 0 | 79% | |
| Jul 1, 2026 | 2 | 9 | 3 | 0 | 0 | 79% | |
| Jun 1, 2026 | 2 | 9 | 3 | 0 | 0 | 79% | |
| May 1, 2026 | 2 | 9 | 3 | 0 | 0 | 79% | |
| Apr 1, 2026 | 2 | 9 | 3 | 0 | 0 | 79% | |
| Mar 1, 2026 | 2 | 9 | 3 | 0 | 0 | 79% | |
| Feb 1, 2026 | 2 | 9 | 3 | 0 | 0 | 79% |
Price targets
Where 12 covering analysts think ZLAB trades over the next 12 months.
$33.14 +36.2% upside Strong Buy
Current$24.33 Low$24.25 Median$31.84 High$50.00 12 analysts
$24.25$50.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
20 SEC filing reports analyzed · 1 bullish, 5 bearish, 0 mixed, 14 neutral · avg impact 3.8/10.
NEUTRALCLUSTER2/10
Two Zai Lab insiders — Director William Lis and CFO Yajing Chen — sold a combined $220K in open-mark
Aug 22, 2026
NEUTRALCLUSTER2/10
A small insider selling cluster at Zai Lab involved a director selling $213K in open-market shares a
Aug 19, 2026
NEUTRALCLUSTER2/10
Two Zai Lab insiders, including CFO Chen Yajing and Director Lis William, sold a combined $228K in o
Aug 14, 2026
NEUTRAL1442/10
Director William Lis filed a Form 144 to sell 8,506 American Depositary Shares (ADS) valued at appro
Aug 12, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Nov 30, 2026
fda_pdufa
PDUFA: ZLAB — povetacicept in immunoglobulin A nephropathy (IgAN) — 2026-11-30
FDA target action date 2026-11-30 for ZLAB (Zai Lab Ltd). Drug: povetacicept. Indication: immunoglobulin A nephropathy (IgAN). PDUFA target action dat
Sep 10, 2026
short_volume
Short Volume: ZLAB — 86.2% short (0.5M / 0.6M)
Short: 512,428 | Exempt: 0 | TRF Vol: 594,368 | Short Ratio: 86.2% | Off-exchange volume (dark pool + OTC)
Aug 24, 2026
ftd
FTD: ZLAB — 22,070 shares ($0.6M) failed to deliver
Settlement: 20260824, Price: $26.01, FTD Value: $574,040.7, ZAI LAB LTD
Aug 18, 2026
short_volume
Short Volume: ZLAB — 84.8% short (0.5M / 0.6M)
Short: 542,467 | Exempt: 700 | TRF Vol: 639,444 | Short Ratio: 84.8% | Off-exchange volume (dark pool + OTC)
Aug 17, 2026
ftd
FTD: ZLAB — 25,154 shares ($0.7M) failed to deliver
Settlement: 20260817, Price: $25.90, FTD Value: $651,488.6, ZAI LAB LTD
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.56 | $-0.67–$-0.49 | -71.0% | -5.4% | 2↑ 3↓ | $0.1B | 6 |
| Next Q | $-0.62 | $-1.03–$-0.42 | -34.3% | -12.9% | 2↑ 3↓ | $0.1B | 6 |
| Current FY | $-2.20 | $-2.76–$-1.60 | -37.2% | -0.4% | 6↑ 3↓ | $0.4B | 10 |
| Next FY | $-2.11 | $-3.15–$-1.17 | 3.9% | -9.3% | 0↑ 9↓ | $0.6B | 10 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.564 | — |
| 7d ago | $-0.576 | +0.012 |
| 30d ago | $-0.536 | -0.029 |
| 60d ago | $-0.527 | -0.037 |
| 90d ago | $-0.527 | -0.037 |
Institutional ownership
Which big funds own ZLAB (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $538.2M total value (28,341,537 shares) as of 2026-Q2. Top holders: RTW, RA, FMR.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 6,574,032 | $124.9M | 23.2% | — |
| RA CAPITAL MANAGEMENT, L.P. | 5,743,533 | $109.1M | 20.3% | NEW |
| FMR LLC | 2,815,214 | $53.5M | 9.9% | DOUBLED +123.0% |
| GOLDMAN SACHS GROUP INC | 2,315,480 | $44.0M | 8.2% | DOUBLED +1993.8% |
| Woodline Partners LP | 2,207,293 | $41.9M | 7.8% | NEW |
| BAMCO INC /NY/ | 1,623,694 | $30.9M | 5.7% | — |
| TWO SIGMA INVESTMENTS, LP | 1,299,394 | $24.7M | 4.6% | — |
| CITADEL ADVISORS LLC | 1,284,706 | $24.4M | 4.5% | — |
| BlackRock, Inc. | 664,462 | $12.6M | 2.3% | ADD +36.2% |
| JANE STREET GROUP, LLC | 476,541 | $9.1M | 1.7% | ADD +77.9% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| FMR LLC | DOUBLED | 1,262,391 | 2,815,214 | +123.0% | $53.5M |
| GOLDMAN SACHS GROUP INC | DOUBLED | 110,587 | 2,315,480 | +1993.8% | $44.0M |
| Woodline Partners LP | NEW | — | 2,207,293 | — | $41.9M |
| JANE STREET GROUP, LLC | ADD | 267,926 | 476,541 | +77.9% | $9.1M |
| Aberdeen Group plc | ADD | 237,739 | 311,294 | +30.9% | $5.9M |
| CITIGROUP INC | DOUBLED | 959 | 300,775 | +31263.4% | $5.7M |
| BNP Paribas Asset Management Holding S.A. | DOUBLED | 116,560 | 246,982 | +111.9% | $4.7M |
| Hudson Bay Capital Management LP | DOUBLED | 30,000 | 215,000 | +616.7% | $4.1M |
| D. E. Shaw & Co., Inc. | DOUBLED | 63,243 | 141,158 | +123.2% | $2.7M |
| DIMENSIONAL FUND ADVISORS LP | TRIM | 174,234 | 101,997 | -41.5% | $1.9M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
14 insiders, 50 transactions. Net -$5.3M — $33.1K bought, $5.3M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 19, 2026 | Chen Yajing | Chief Financial Officer | SELL | 260 | $27.00 | $7.0K |
| Aug 14, 2026 | Chen Yajing | Chief Financial Officer | EXERCISE | 1,250 | — | — |
| Aug 14, 2026 | Chen Yajing | Chief Financial Officer | TAX W/H | 427 | $25.90 | $11.1K |
| Aug 12, 2026 | Lis William | Director | SELL | 8,506 | $25.00 | $212.7K |
| Aug 11, 2026 | Chen Yajing | Chief Financial Officer | SELL | 619 | $25.00 | $15.5K |
| Jul 2, 2026 | Du Ying | Chairperson & CEO | EXERCISE | 11,048 | — | — |
| Jul 2, 2026 | Du Ying | Chairperson & CEO | TAX W/H | 4,348 | $19.12 | $83.1K |
| Jul 2, 2026 | Du Ying | Chairperson & CEO | AWARD | 80,393 | — | — |
| Jul 1, 2026 | Du Ying | Chairperson & CEO | EXERCISE | 18,000 | — | — |
| Jul 1, 2026 | Du Ying | Chairperson & CEO | TAX W/H | 7,083 | $19.15 | $135.6K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ZLAB.
Shares short
8,156,879
Settlement Sep 15, 2026
Change vs prior
+1.7%
Semi-monthly cycle
Days to cover
9.2
At avg daily volume
Of shares outstanding
≈7.3%
Estimate — not % of float
All ZLAB filing & press-release reports (20)
- CLUSTER reportAug 22, 2026
- CLUSTER reportAug 19, 2026
- CLUSTER reportAug 14, 2026
- 144 reportAug 12, 2026
- CLUSTER reportJul 7, 2026
- CLUSTER reportJul 2, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 21, 2026
- CLUSTER reportMay 21, 2026
- CLUSTER reportMay 19, 2026
- 8-K reportMay 7, 2026
- DEFA14A reportApr 28, 2026
- 144 reportApr 6, 2026
- 144 reportApr 6, 2026
- CLUSTER reportMar 19, 2026
- CLUSTER reportMar 16, 2026
- CLUSTER reportMar 12, 2026
- CLUSTER reportMar 10, 2026
- CLUSTER reportMar 6, 2026
- 8-K reportFeb 26, 2026